Tacrolimus once-daily formulation: In the prophylaxis of transplant rejection in renal or liver allograft recipients

Drugs

Volumn 67, Issue 13, 2007, Pages 1931-1943

  Cross, Sarah A ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADVAGRAF; AMINOGLYCOSIDE; BASILIXIMAB; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; GYRASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ALOPECIA; AREA UNDER THE CURVE; BACTERIAL INFECTION; CELLULITIS; CHOLANGITIS; CHOLESTASIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROENTERITIS; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCISIONAL HERNIA; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LOOSE FECES; LOWER ABDOMINAL PAIN; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL EDEMA; PNEUMONIA; PROPHYLAXIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINUSITIS; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS INFECTION;

DELAYED-ACTION PREPARATIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 34548332533     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767130-00012     Document Type: Review

References (33)

1. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63 (12): 1247-97
2. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004 Mar 15; 77 (5): 769-76
3. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839-48
4. European Medicines Agency. Advagraf: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Jun 29]
5. Astellas Pharma Ltd. Prograf 0.5mg, 1mg, 5mg hard capsules: conversummary of product characteristics [online]. Available from URL: http://emc.medicines. org.uk [Accessed 2007 Mar 28]
6. Astellas Pharma US Inc. Prograf® (tacrolimus capsules/tacrolimus injection): prescribing information [online]. Available from URL: http://www.fda.gov/cder [Accessed 2007 Mar 28]
7. Novartis Pharmaceuticals UK Ltd. Neoral soft gelatin capsules, Neoral oral solution: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2007 May 10]
8. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000 Feb; 59 (2): 323-89
9. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999 Mar 27; 353: 1083-91
10. Miller JL, Ericson SG. Cyclosporin A and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo. Immunopharmacol Immunotoxicol 2007; 29 (1): 105-18
11. Serón D, O'Valle F, Moreso F, et al. Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. Transplantation 2007 Mar 15; 83 (5): 649-52
12. Fernandez LA, Lehmann R, Luzi L, et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999 Nov 27; 68 (10): 1532-41
13. Silva Jr HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients [published erratum appears in Am J Transplant 2007; 7 (6): 1682]. Am J Transplant 2007 Jan 11; 7 (3): 595-608
14. Harold Y. A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (tacrolimus)/MMF, extended release (XL) tacrolimus/MMF and Neoral® (cyclosporine)/MMF in de novo kidney transplant recipients. Tacrolimus Extended Release de novo Kidney Study Group [abstract no. 144]. Am J Transplant 2007 May; 7 (s2): 183
15. Boots JMM, Christiaans MHL, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64 (18): 2047-73
16. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo kidney transplant recipients. Tacrolimus Modified Release Kidney Study Group [abstract no. 132]. Am J Transplant 2005; 5 Suppl. 11: 190
17. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37 (2): 867-70
18. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients. Tacrolimus Modified Release Liver Study Group [abstract no. 859]. Am J Transplant 2005; 5 Suppl. 11: 374
19. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37 (2): 1211-3
20. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007 Jun; 7 (6): 1609-15
21. European Medicines Agency. Advagraf: scientific discussion [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Jun 7]
22. Data on file. Astellas Pharma US, Inc, 2007
23. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43 (10): 623-53
24. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol 2007 Apr; 21 (2): 191-7
25. Baraldo M, Furlanut M. Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet 2006; 45 (8): 775-88
26. Choi JH, Lee YJ, Jang SB, et al. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol. Epub 2007 Mar 28
27. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006 Nov; 6 (11): 2706-13
28. Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007 Feb; 81 (2): 228-34
29. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007 Jun 27; 83 (12): 1648-51
30. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007 Jun 27; 83 (12): 1639-42
31. Astellas Pharma Inc. Astellas receives an European Commission approval for Advagraf ® [media release]. 2007 Apr 27
32. Astellas Pharma Inc. Astellas receives an action letter from FDA for NDA of FK506 MR in the U.S. [media release]. 2007 Jan 23
33. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2007 Jun 19]